MindRank AI Participates in the 4th International MAH Collaboration and Innovation Conference to Advance AI-Driven Drug Discovery
MindRank
AI Drug Developer
On September 20, 2025, the sub-forum of the 4th International MAH Cooperation and Innovation Conference was successfully held in Qiantang District, Hangzhou. Under the theme of "AI Empowerment, Intelligence Unlocks the Future," Niu Zhangming, founder and CEO of MindRank, was invited to attend.
At the conference, MindRank and the organizer jointly launched the "Qiantang Smart Manufacturing Innovative Drug Consortium," aiming to promote the deep integration of AI and pharmaceutical R&D and build a new ecosystem for the innovative drug industry. At the roundtable forum on "AI Empowering Healthcare: Implementation Scenarios, Challenges, and Solutions," Niu Zhangming and experts from Zhejiang University, Tencent Health, Pfizer Innovation Center, and other institutions conducted in-depth discussions on AI technology implementation, data governance, and model iteration.
Niu Zhangming stated that the synergy between AI and institutional innovation is injecting strong momentum into the high-quality development of the pharmaceutical industry. This conference has provided a high-level platform for cross-disciplinary collaboration, showcasing the broad prospects of "AI + pharmaceuticals" integration. As an innovative company in the AI drug development sector, MindRank Ltd. has further deepened its industry cooperation through this exchange.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby enabling more diseases to be treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamics simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was included in Fortune magazine's IMPACT list as one of "China's most socially impactful startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank's Self-Developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai